Phaarmasia Past Earnings Performance
Past criteria checks 0/6
Phaarmasia's earnings have been declining at an average annual rate of -45.5%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 4.9% per year.
Key information
-45.5%
Earnings growth rate
-45.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 4.9% |
| Return on equity | -4.6% |
| Net Margin | -1.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Phaarmasia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 293 | -5 | 19 | 0 |
| 30 Jun 24 | 320 | 0 | 18 | 0 |
| 31 Mar 24 | 306 | -5 | 18 | 0 |
| 31 Dec 23 | 281 | -11 | 18 | 0 |
| 30 Sep 23 | 310 | -11 | 17 | 0 |
| 30 Jun 23 | 290 | -12 | 17 | 0 |
| 31 Mar 23 | 275 | -13 | 17 | 0 |
| 31 Dec 22 | 242 | -13 | 15 | 0 |
| 30 Sep 22 | 201 | -15 | 15 | 0 |
| 30 Jun 22 | 187 | -19 | 14 | 0 |
| 31 Mar 22 | 172 | -15 | 14 | 0 |
| 31 Dec 21 | 189 | -12 | 13 | 0 |
| 30 Sep 21 | 199 | -5 | 14 | 0 |
| 30 Jun 21 | 194 | 3 | 15 | 0 |
| 31 Mar 21 | 204 | 3 | 15 | 0 |
| 31 Dec 20 | 204 | 7 | 15 | 0 |
| 30 Sep 20 | 218 | 7 | 15 | 0 |
| 30 Jun 20 | 215 | 7 | 15 | 0 |
| 31 Mar 20 | 245 | 5 | 16 | 0 |
| 31 Dec 19 | 317 | 12 | 18 | 0 |
| 30 Sep 19 | 299 | 9 | 18 | 0 |
| 30 Jun 19 | 298 | 6 | 18 | 0 |
| 31 Mar 19 | 257 | 8 | 17 | 0 |
| 31 Dec 18 | 169 | 0 | 17 | 0 |
| 30 Sep 18 | 192 | 3 | 18 | 0 |
| 30 Jun 18 | 201 | 5 | 18 | 0 |
| 31 Mar 18 | 202 | 6 | 18 | 0 |
| 31 Dec 17 | 165 | 2 | 17 | 0 |
| 30 Sep 17 | 164 | 2 | 17 | 0 |
| 30 Jun 17 | 158 | 2 | 16 | 0 |
| 31 Mar 17 | 144 | 2 | 16 | 0 |
| 31 Dec 16 | 130 | 0 | 16 | 0 |
| 30 Sep 16 | 124 | 0 | 15 | 0 |
| 30 Jun 16 | 138 | 0 | 15 | 0 |
| 31 Mar 16 | 132 | 0 | 16 | 0 |
| 31 Dec 15 | 132 | 2 | 23 | 0 |
| 30 Sep 15 | 130 | 1 | 23 | 0 |
| 30 Jun 15 | 116 | 1 | 25 | 0 |
| 31 Mar 15 | 123 | 1 | 14 | 0 |
| 31 Dec 14 | 118 | 4 | 20 | 0 |
| 30 Sep 14 | 112 | 3 | 20 | 0 |
| 30 Jun 14 | 132 | 4 | 19 | 0 |
| 31 Mar 14 | 152 | 4 | 18 | 0 |
| 31 Dec 13 | 146 | 1 | 17 | 0 |
Quality Earnings: 523620 is currently unprofitable.
Growing Profit Margin: 523620 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 523620 is unprofitable, and losses have increased over the past 5 years at a rate of 45.5% per year.
Accelerating Growth: Unable to compare 523620's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 523620 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.5%).
Return on Equity
High ROE: 523620 has a negative Return on Equity (-4.59%), as it is currently unprofitable.